Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | NADPH oxidoreductase, putative | 0.0268 | 0.9522 | 0.5 |
Entamoeba histolytica | modulator of drug activity B homolog, putative | 0.0067 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0067 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0201 | 0.6351 | 0.6669 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Giardia lamblia | NADPH oxidoreductase, putative | 0.0268 | 0.9522 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | NAD(P)H dehydrogenase, putative | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Giardia lamblia | NADPH oxidoreductase, putative | 0.0268 | 0.9522 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | NAD(P)H dehydrogenase, putative | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | NAD(P)H dehydrogenase, putative | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Entamoeba histolytica | iron-sulfur flavoprotein, putative | 0.0067 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0268 | 0.9522 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.